SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is currently a central point of debate as investors weigh the company's massive contract backlogs and multi-billion-dollar financing partnerships against aggressive short-seller reports questioning its supply chain transparency. While bulls highlight Bloom's critical role in providing localized power for AI data centers as a major growth driver, the community remains divided over the stock's high volatility and the potential impact of raw material procurement allegations.

Digital Turbine, Inc. is a mobile growth platform that offers solutions for advertisers, publishers, carriers, and device original equipment manufacturers (OEMs). The firm operates through the On Device Solutions (ODS) and App Growth Platform (AGP) segments. The ODS segment generates revenue from the delivery of mobile application media or content to end users with solutions for all participants in the mobile application ecosystem that want to connect with end users and consumers who hold the device. This includes mobile carriers and device OEMs that participate in the app economy, app publishers and developers, and brands and advertising agencies. The AGP segment provides platforms that allow mobile app publishers and developers to monetize their monthly active users via display, native, and video advertising. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

Digital Turbine (APPS) is seeing aggressive investor interest and a potential re-rating as the market pivots toward its role in the AI inference and mobile distribution economy. The community is actively debating the stock's turnaround narrative, with bulls highlighting strategic partnerships and improving financial guidance, while bears remain focused on the company's legacy debt and high short interest.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

The community is actively discussing the potential of memecoin assets and their on-chain liquidity, with $PEPE and $4CHAN trending as investors analyze the risks and rewards of these decentralized projects. Traders remain sharply divided, debating whether to accumulate these tokens during volatility or if market sentiment and broader political discussions are negatively impacting the sector's growth.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is facing heightened market scrutiny following a Complete Response Letter from the FDA for its Hunter syndrome gene therapy, with investors now shifting their focus toward the company's upcoming pivotal DMD data and milestone payments from its AbbVie partnership. Community sentiment remains polarized, as stakeholders weigh the regulatory challenges against the long-term potential of the company's broader gene therapy pipeline.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is trending as investors weigh strong production delivery momentum and a growing defense backlog against persistent headwinds from geopolitical tensions and ongoing certification scrutiny. The community remains deeply divided, with many traders actively debating whether the stock is a long-term value play poised for an inflection point or a stagnant, underperforming asset plagued by operational and headline-driven volatility.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Emergent Biosolutions is experiencing significant market interest driven by ongoing short-selling pressure and anticipation surrounding potential government contract awards for biodefense products like ACAM2000 and Ebanga. The community is actively debating the company's turnaround strategy under leadership, with polarized discussions focused on debt management, recent financial results, and the outlook for government procurement in a volatile geopolitical environment.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond is trending as the stock experiences extreme volatility following a positive earnings report that marked the company's first revenue growth in years, only for shares to plummet amid community concerns regarding acquisition strategies and share dilution. Investors are actively debating the potential of the 'Everything Home' retail pivot while grappling with the stock's tendency to reverse gains during aggressive intraday moves.

iShares Bitcoin Trust ETF (The) - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

IBIT is experiencing heightened volatility and increased put activity as investors weigh record outflows and Bitcoin's ongoing price correction. The community is actively debating whether current support levels signal a long-term buying opportunity or a deeper downward trend, with many traders closely monitoring institutional flows and technical levels for signs of a potential reversal.

Stellantis NV engages in the designing, engineering, manufacturing, distributing, and selling of vehicles and components. It offers its products under the Abarth, Alfa Romeo, Chrysler, Citroën, Dodge, DS Automobiles, Fiat, Jeep, Lancia, Maserati, Opel, Peugeot, Ram Trucks, Vauxhall, Free2move, and Leasys brands. The company was founded on April 1, 2014 and is headquartered in Hoofddorp, the Netherlands.

Stellantis N.V

Stellantis stock is facing significant downward pressure following a historic annual loss driven by massive write-downs on electric vehicle platforms. The community is sharply divided, with some investors viewing the current valuation as a deep-value opportunity for a long-term turnaround, while others remain skeptical due to high dealer inventory levels and ongoing concerns about management's strategic direction.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ouster Inc. is capturing significant community attention as it positions its Rev8 digital lidar platform as a foundational perception layer for the Physical AI and robotics sector. Investors are actively discussing the company's recent Build America, Buy America (BABA) compliance, which unlocks federal funding eligibility and validates its strategy to scale into smart infrastructure and autonomous systems.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

AbCellera (Nasdaq: ABCL) will announce its second quarter 2026 financial results on Wednesday, August 5, 2026, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that...

Are You Looking for a Top Momentum Pick? Why AbCellera Biologics Inc. (ABCL) is a Great Choice

Does AbCellera Biologics Inc. (ABCL) have what it takes to be a top stock pick for momentum investors? Let's find out.

AbCellera Appoints Dr. Lynn Seely to its Board of Directors

AbCellera (Nasdaq: ABCL) today announced the appointment of Lynn Seely, M.D., to its Board of Directors as an independent director. Dr. Seely is a respected executive leader with a proven track record of successfully developing new medicines in endocrinology, oncology, and womens health. I am...

Is ABCELLERA BIOLG (ABCL) Stock Outpacing Its Medical Peers This Year?

Here is how AbCellera Biologics Inc. (ABCL) and Agilon Health (AGL) have performed compared to their sector so far this year.

As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the Data

As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the Data As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the Data PR Newswire NEW YORK, July 1, 2026 Issued on behalf...

Why Did SLS, MRNA, ABCL Stocks Surge To 52-Week Highs Last Week?

Equity

Investor interest has focused on companies nearing key milestones, signing major partnerships, or improving their business outlook. 


ABCELLERA BIOLG (ABCL) Surges 7.1%: Is This an Indication of Further Gains?

ABCELLERA BIOLG (ABCL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last?

Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor Therapies

Jazz Pharmaceuticals teams up with AbCellera to discover and develop T-cell-engaging antibodies for GI cancers and other solid tumors.

Is ABCELLERA BIOLG (ABCL) Outperforming Other Medical Stocks This Year?

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$6.80
Prev Close	$7.29
Open	$7.29
Dividend Yield	0.00%
50-Day Moving Average	$5.68
Beta	1.69
Avg. Volume	7.73M
PE Ratio	-14.18

52-Week High	$8.44
52-Week Low	$2.75
Market Capitalization	$2.23B
EPS (Annual)	-$0.4901
Price to Book	2.20
Revenue Per Employee	$133,679.71

Feed

News

Sentiment

Earnings

Fundamentals

Info

ABCLAbCellera Biologics Inc

Latest ABCL News